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Abstract
BACKGROUND & AIMS—Patients with Crohn’s disease (CD), but not ulcerative colitis (UC), 
of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than 
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patients with longer disease duration. Little is known about the association between disease 
duration and response to other 
biologicagents.WeaimedtoevaluateresponseofpatientswithCDorUCtovedolizumab,stratifiedby 
disease duration.
METHODS—We analyzed data from a retrospective, multicenter, consortium of patients with CD 
(n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. 
Using time to event analyses, we compared rates of clinical remission, corticosteroid-free 
remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) 
and later-stage (>2 years) CD or UC. We used Cox proportional hazards models to identify factors 
associated with outcomes.
RESULTS—Within 6 months initiation of treatment with vedolizumab, significantly higher 
proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% 
vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all 
comparisons). After adjusting for disease-related factors including previous exposure to TNF 
antagonists, patients with early-stage CD were significantly more likely than patients with later-
stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02–2.49), 
CSFR (aHR, 3.39; 95% CI, 1.66–6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06–
3.39). In contrast, disease duration was not a significant predictor of response among patients with 
UC.
CONCLUSIONS—Patients with CD for 2 years or less are significantly more likely to achieve a 
complete response, CSFR, or endoscopic response to vedolizumab than patients with longer 
disease duration. Disease duration does not associate with response vedolizumab in patients with 
UC.
Keywords
Inflammatory Bowel Disease; Integrin; Monoclonal Antibody Therapy; Time
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) 
that result in chronic inflammation of the gastrointestinal tract with periods of remission 
alternating with relapse.1,2 It is increasingly recognized that IBD, and CD in particular, are 
progressive diseases in which patients accumulate bowel damage over time that can lead to 
irreversible complications.3–5 There seems to be an optimal window of opportunity in which 
early effective intervention may improve outcomes and alter the natural history of the 
disease, akin to the evolving practice in rheumatoid arthritis.6,7
Accumulating evidence suggests that treatment with biologics targeting tumor necrosis 
factor (TNF)-α may be more effective when initiated early in the disease course. In a post 
hoc analysis of the PRECiSE 2 trial of certolizumab in CD, patients with disease duration 
less than 2 years had an 82% response rate at 26 weeks, compared with 59% among those 
with longer disease duration.8 Similar findings emerged from post hoc analyses of the 
CHARM trial of adalimumab in CD, where higher clinical remission rates at 56 weeks were 
seen among patients with disease duration less than 2 years (43%) compared with 2–5 years 
(30%) or greater than 5 years (28%), even after controlling for potential confounding factors, 
such as prior TNF antagonist exposure.9
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Whether this treatment-modifying effect of early disease duration is unique to the TNF 
antagonist drug class or extends to other treatment agents (eg, anti-integrins) is not clear. A 
post hoc analysis of the ENCORE trial of natalizumab in CD found that disease duration ≤3 
years was associated with a higher proportion of patients in clinical remission at 12 weeks 
than the overall treatment population (52% vs 38%).10 No studies published to date have 
evaluated response and remission rates to vedolizumab stratified by disease duration.
We aimed to evaluate the impact of disease duration on vedolizumab effectiveness using a 
multicenter consortium cohort study of the real-world experience with vedolizumab. We 
analyzed rates of clinical and endoscopic remission in patients with CD and UC treated with 
vedolizumab, comparing those with shorter disease duration (≤2 years) with those with 
longer-standing (>2 years) disease.
Methods
Study Design
This is a retrospective review of the VICTORY Consortium registry.11 In brief, this is a 
multicenter collaborative research group repository where outcomes are pooled for patients 
with IBD treated with biologics. Institutional review board approval was obtained from each 
site for ongoing data collection and transfer. Data were collected individually by sites using 
a standardized data collection form and transferred (after deidentification) to the 
coordinating site (University of California, San Diego) for data compilation and analysis. 
The current analysis represents data collected between May 2014 and December 2016. The 
results of this study are reported in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines for cohort studies.12
Variables
Data on variables of interest were collected including: patient characteristics (age at 
diagnosis, age at vedolizumab initiation, gender, smoking status, body mass index), disease 
characteristics (prior hospitalizations, prior surgeries, disease-related complications or 
extraintestinal manifestations, and phenotype classified according to the Montreal 
classifications for CD and UC), and treatment history (steroids, immunomodulators, and 
TNF antagonists; duration of use; indication for discontinuation; and complications). 
Variables of interest specific to vedolizumab use were baseline disease severity (endoscopic, 
radiographic, or clinical assessments), concomitant treatments (steroids and/or 
immunomodulators), infusions (dates, intervals, premedications), and follow-up assessments 
(endoscopic, radiographic, or clinical assessments). Clinical assessments were classified as 
severe versus nonsevere based on physician global assessment, where mild or moderate 
severity were classified as nonsevere. The primary variable of interest was disease duration, 
defined as a dichotomous variable. Shorter duration was defined as ≤2 years and longer 
duration as >2 years at the time of vedolizumab initiation. This definition is consistent with 
most prior data on the impact of disease duration on the efficacy of biologics.8,9
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Participants
Individuals were included in the current analysis if they met the following criteria: (1) 
confirmed diagnosis of CD or UC based on clinical and endoscopic or radiographic data, (2) 
active clinical symptoms attributed to CD or UC before starting vedolizumab, and (3) had at 
least 1 clinical and/or endoscopic follow-up after initiation of therapy. Patients started on 
vedolizumab for indeterminate colitis or pouchitis, or those in clinical remission at the time 
of starting vedolizumab (eg, patients with CD transitioned from natalizumab to vedolizumab 
for safety or initiated on vedolizumab for postoperative prophylaxis of CD) were excluded.
Outcomes
The primary outcomes of interest were the cumulative rates for clinical remission, 
corticosteroid-free remission (CSFR), or endoscopic remission at 6 months. Timing of 
assessments for response followed routine practice standards as dictated by local sites with 
no predetermined or standardized time-point of assessment. Clinical assessments for 
remission were performed based on physician global assessment, where remission was 
defined as complete resolution of all CD- or UC-related symptoms by treating physician 
evaluation. The assessment of CSFR (performed only in patients on prednisone or 
budesonide at the time of initiation of vedolizumab) was defined as tapering off steroids 
completely, achieving clinical remission, and no repeat steroid prescription within 4 weeks 
of tapering. Endoscopic remission was defined as the absence of ulcers and/or erosions in 
CD or a Mayo endoscopic score of ≤1 in UC.13,14 Endoscopic categorization was done by 
local study investigators and was reverified by a coordinating study investigator (P.S.D.) 
using deidentified endoscopy reports, with any discrepancies resolved through consensus 
between the study sites and the coordinating site.
Statistical Analysis
Continuous variables were presented as means and standard deviations, or as medians and 
interquartile ranges based on data distribution. Categorical and binary variables were 
presented as proportions or percentages. For the comparison of baseline continuous 
variables, we used the independent sample t test (2 group comparisons) or 1-way analysis of 
variance with Bonferroni correction (3 or more group comparisons). For the comparison of 
baseline binary variables, we used the Pearson chi-square or Fisher exact tests. Primary and 
secondary outcomes were described quantitatively with Kaplan-Meier survival and time-to-
event analyses. Data were collected at clinical follow-up times determined by each treating 
physician, and 6-month cumulative outcomes were used in this study to maximize available 
data. A sensitivity analysis was performed by transforming disease duration into a 
categorical variable (≤2 years, >2 years to ≤5 years, and >5 years), and outcomes were 
described quantitatively with Kaplan-Meier survival and time-to-event analyses to 
understand if the definition for early disease in CD could be extended to 5 years.
Cox proportional hazards regression analyses were performed to identify independent 
predictors of treatment outcomes. All baseline variables from the univariable analyses with a 
P value of < .20 were fitted and a backward model selection approach was taken where the 
variable with the highest P value was sequentially selected out until all remaining variables 
in the model had a P value of < .05. Prior TNF antagonist exposure was included in all 
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multivariable models, irrespective of P value. An assessment of interaction terms was then 
performed and interactions were retained if they had a P value of < .05.
Hazard ratios (HR) with 95% confidence interval (CI) are presented for independent 
predictors where HR <1 indicated a predictor was associated with a reduced probability for 
achieving the outcome and HR >1 indicated a predictor was associated with an increased 
probability for achieving the outcome. Two-sided P values < .05 were considered 
statistically significant. Statistical analyses were performed using Stata statistical software 
(College Station, TX).
Study Sponsor
Takeda Pharmaceuticals provided funding for statistical support to analyze the data. Takeda 
Pharmaceuticals and associated employees did not have access to any of the data, and all 
data analyses were performed at the University of California San Diego by the VICTORY 
Consortium investigators or statisticians.
Results
Crohn’s Disease: Demographics
A total of 650 patients with CD were included. In the CD group, there were significant 
differences in baseline disease and treatment-related characteristics between those with 
disease duration ≤2 years and those with duration greater than 2 years (Table 1). Patients 
with longer disease duration had higher rates of CD-related complications including 
stricturing and penetrating disease (70% and 38% vs 39% and 23%, respectively; P < .05 for 
both comparisons). A higher percentage of longer duration patients had failed TNF 
antagonists (77% vs 60%; P < .01), and 70% of those in the longer disease duration group 
previously had failed at least 2 TNF antagonists versus 34% in the shorter disease duration 
group (P < .01).
Crohn’s Disease: Cumulative Rates and Predictors of Remission
The cumulative rates for clinical remission, CSFR, and endoscopic remission for CD at 6 
months were significantly higher in the early disease duration group than in the longer 
disease duration group (Table 2, Figure 1). When further stratifying the long disease 
duration into >2 years to ≤5 years versus >5 years, no differences were seen between these 2 
groups across any of the primary endpoints (Supplementary Figure 1).
On multivariable analyses for CD, disease duration ≤2 years remained a significant predictor 
of clinical remission (adjusted HR [aHR], 1.59; 95% CI, 1.02–2.49), CSFR (aHR, 3.39; 95% 
CI, 1.66–6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06–3.39) (Table 3).
Ulcerative Colitis: Demographics
A total of 437 patients with UC were included. In contrast to CD, there were few differences 
in baseline demographic characteristics between the early and longer disease duration of UC 
groups (Table 1). There was a comparable distribution of disease extent according to the 
Montreal classification between the 2 groups, a similar number of steroid-refractory or 
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steroid-dependent patients, and a comparable percentage of TNF antagonist naive patients 
(44% in both groups). Notably, among those who had failed a prior TNF antagonist, there 
was a higher percentage of individuals in the longer disease duration group who had failed 2 
or more TNF antagonist medications (25% vs 15%; P = .05) than in the shorter disease 
duration group.
Ulcerative Colitis: Cumulative Rates and Predictors of Remission
Among patients with UC, there were no significant differences in any of the outcomes 
between those with disease duration ≤2 years and those with longer disease duration (Table 
2). Univariable and multivariable analyses were not performed for UC because initial time-
to-event analyses revealed no differences in outcomes between early and longer disease 
duration groups.
Discussion
In this multicenter consortium study, we observed that treatment with vedolizumab in the 
first 2 years after diagnosis of CD is associated with higher rates of clinical, corticosteroid-
free, and endoscopic remission than treatment initiated later in the disease course. This 
improved treatment response was seen across all of the study endpoints in CD, and persisted 
after controlling for other predictors of treatment outcome, including prior TNF antagonist 
therapy. In contrast, no association between disease duration and treatment outcome was 
seen in patients with UC.
In recent years, there has been an intense interest in early, aggressive treatment of CD, to 
reduce the long-term morbidity associated with progressive bowel damage.15 Early 
intervention is thought to target CD in a “window of opportunity” before irreparable bowel 
damage sets in.16 A lower percentage of patients in our study in the early CD group had 
fistulizing or penetrating complications, which supports this hypothesis. A second theory 
invokes different immune responses in early versus late CD,17 including differential T-cell 
immune responses to interleukin-12 stimulation in children with early versus late CD18 and 
increases in peripheral T-helper cell type 17 cells in patients with late versus early CD.19 
Finally, the microbiome plays an important role in responsiveness to therapy in IBD,20 and 
treatment-naive early IBD may have a distinct microbiota composition that can impact 
therapy outcomes.21
The landmark “Step-up/Top-down” study22 was the first to show in a randomized controlled 
trial that early aggressive therapy with combined infliximab and azathioprine was superior to 
conventional step-up approach in early CD for achieving early remission. Similarly, a post 
hoc analysis of the landmark SONIC trial23 stratifying by disease duration demonstrated 
higher efficacy in achieving rigorous endpoints, such as a composite of clinical remission, 
mucosal healing, and C-reactive protein normalization in patients with CD treated within 18 
months of diagnosis.24 Similar findings have been found with adalimumab and certolizumab 
monotherapy in early CD.8,9 In contrast to TNF antagonist medications, immunomodulators 
have not been shown to be more effective in early disease in achieving remission and 
mucosal healing.25,26
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Our data add to the growing literature on early intervention in CD and demonstrate that 
improved outcomes with early treatment are not a limited class effect of TNF antagonist 
therapy. Importantly, this effect was seen even in a relatively refractory cohort, with 60% of 
patients with CD treated early with vedolizumab already having failed at least 1 TNF 
antagonist. This finding represents an important step in targeting disease modification in 
CD, because vedolizumab has also been shown to have an excellent safety profile,27,28 
although studies with long-term follow-up are still needed. Therefore, while balancing the 
benefits of early intervention with the possible side effects of increased duration of drug 
exposure, vedolizumab may be an excellent candidate for early initiation.
In contrast to the emerging literature on the benefits of early intervention in CD, there is a 
paucity of data on early intervention in UC, and whether UC is a progressive disease like CD 
remains unclear. In a retrospective cohort study of the early initiation of infliximab or 
adalimumab within 3 years of UC diagnosis, Ma et al29 found no difference in the rates of 
UC-related hospitalizations, secondary loss of response, or colectomy between early and late 
treatment groups. Similarly, Mandel et al30 found that early TNF antagonist use in CD, but 
not in UC, was associated with decreased hospitalization rates. We are also unaware of any 
post hoc analyses of clinical trials in UC demonstrating any impact of disease duration on 
treatment efficacy. Our data are consistent with these prior retrospective studies in showing 
no difference between early and late initiation of vedolizumab on short-term treatment 
outcomes in UC.
The reason for the differing impact of early treatment in UC versus CD is not clear. One 
hypothesis is that demonstration of disease modification in UC may require a longer 
duration of follow-up. The risk of colorectal malignancy has been shown to correlate with 
the intensity and longevity of endoscopic and histologic intestinal inflammation,31 and 
therapy that can effectively promote and maintain mucosal healing may decrease the long-
term risk of colorectal cancer.32–35 Histologic healing as an independent endpoint has 
garnered significant attention in recent years36,37 and would be an interesting endpoint for 
future evaluation in our cohort. Similarly, chronic inflammation leading to bowel damage 
and fibrosis in UC may yield poorer functional outcomes because of loss of luminal wall 
compliance and development of anorectal dysfunction and motility disorders.32,38 Whether 
early intervention with vedolizumab and other agents can alter the natural history of UC and 
prevent these complications needs to be explored further in longitudinal studies.
The strengths of our study include the large, real-world, multicenter data set that represents a 
broad population of individuals with IBD. Patients had detailed clinical and endoscopic data 
collected using standardized extraction methods. Our data are concordant with studies of 
TNF antagonist medications in early IBD showing a benefit in early CD but not UC, but 
importantly we extend these findings to vedolizumab, which has not previously been 
observed.
Our study does have several important limitations. The retrospective collection of data 
across multiple institutions and the lack of well-validated clinical indices for measuring 
treatment remission may impact response estimates. Additionally, no central reading of 
endoscopies was performed, but rereview of reports by a single study investigator resulted in 
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<5% reclassification of endoscopic scoring. Furthermore, the follow-up time used for the 
primary outcomes in this study was relatively short and the rates of additional outcomes, 
such as surgeries and hospitalizations, were too low for meaningful analysis. Further data 
collection is needed to assess the durability of the improved response rates in the treatment 
of early CD, and to assess for a possible impact on long-term outcomes in UC. Finally, 
important differences exist in the disease phenotype and treatment experience of the early 
versus late groups, especially in CD. Despite rigorous multivariable modeling to control for 
these factors, there remains the possibility of unmeasured confounders impacting response 
and remission rates.
In summary, we found that vedolizumab-treated patients with CD with early disease (≤2 
years) had significantly improved outcomes with higher rates of clinical, corticosteroid-free, 
and endoscopic remission than those with longer disease duration. In contrast, this 
improvement was not seen in patients with UC with short disease duration treated with 
vedolizumab. The combined safety and efficacy of vedolizumab makes it an attractive 
candidate for early, aggressive intervention in hopes of achieving lasting disease 
modification. Further studies are needed to explore the impact of early use of vedolizumab 
on long-term outcomes and its ability to prevent disease progression in CD and UC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What You Need to Know
Background
Patients with Crohn’s disease (CD), but not ulcerative colitis (UC), of shorter duration 
have higher rates of response to tumor necrosis factor antagonists than patients with 
longer disease duration, but little is known about the association between disease duration 
and response to other biologic agents. We analyzed data from patients with CD or UC 
treated with vedolizumab and used time to event analyses to compare rates of clinical 
remission, corticosteroid-free remission (CSFR), and endoscopic remission between 
patients with early-stage (≤2 years duration) and later-stage (>2 years) CD or UC.
Findings
Patients with CD for 2 years or less were significantly more likely to achieve a complete 
response, CSFR, or endoscopic response to vedolizumab than patients with longer 
disease duration. Disease duration did not associate with response vedolizumab in 
patients with UC.
Implications for patient care
Patients given a diagnosis of CD should begin treatment with anti-TNF agent or 
vedolizumab as soon as possible.
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Figure 1. 
Cumulative rates of remission stratified by disease duration ≤2 years or >2 years. (A) 
Clinical remission. (B) Corticosteroid-free remission. (C) Endoscopic remission.
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Table 2.
Remission Rates at 6 Months Stratified by Disease Duration
Remission rates
Crohn’s disease ≤2 y (n = 62) >2 y (n = 588)
 Clinical remission, %a 38 23
 Corticosteroid-free remission, %a 43 14
 Endoscopic healing, %a 29 13
Ulcerative colitis ≤2 y (n = 109) >2 y (n = 328)
 Clinical remission, % 35 33
 Corticosteroid-free remission, % 22 20
 Endoscopic healing, % 16 22
aSignificant (P < .05) on log-rank analyses.
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2020 February 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Faleck et al. Page 16
Ta
bl
e 
3.
M
ul
tiv
ar
ia
bl
e 
Pr
ed
ic
to
rs
 o
f T
re
at
m
en
t O
ut
co
m
es
 in
 C
ro
hn
’s
 D
ise
as
e
Pr
ed
ic
to
rs
 o
f t
re
a
tm
en
t o
ut
co
m
es
 in
 C
ro
hn
’s
 d
ise
as
e
U
na
dju
ste
d H
R 
(95
%
 C
I)
A
dju
ste
d H
R 
(95
%
 C
I)
Cl
in
ic
al
 re
m
iss
io
n
 
St
ric
tu
rin
g 
or
 p
en
et
ra
tin
g 
ph
en
ot
yp
e
0.
58
 (0
.44
–0
.77
)
0.
69
 (0
.51
–0
.92
)
 
D
ise
as
e 
se
v
er
ity
 (s
ev
er
e 
v
s 
n
o
n
se
v
er
e)
0.
40
 (0
.28
–0
.56
)
0.
53
 (0
.43
–0
.65
)
 
H
os
pi
ta
liz
ed
 in
 p
re
v
io
us
 y
ea
r
0.
66
 (0
.49
–0
.90
)
0.
71
 (0
.52
–0
.97
)
 
D
ise
as
e 
du
ra
tio
n 
≤2
 y
1.
69
 (1
.09
–2
.61
)
1.
59
 (1
.02
–2
.49
)
 
TN
F 
an
ta
go
ni
st 
ex
po
su
re
0.
51
 (0
.34
–0
.77
)
0.
64
 (0
.42
–0
.98
)
Co
rti
co
ste
ro
id
-fr
ee
 re
m
iss
io
n
 
A
lb
u
m
in
1.
47
 (0
.89
–2
.43
)
1.
76
 (1
.04
–2
.97
)
 
TN
F 
an
ta
go
ni
st 
ex
po
su
re
0.
43
 (0
.22
–0
.85
)
0.
40
 (0
.20
–0
.80
)
 
D
ise
as
e 
du
ra
tio
n 
≤2
 y
2.
99
 (1
.59
–5
.64
)
3.
39
 (1
.66
–6
.92
)
En
do
sc
op
ic
 re
m
iss
io
n
 
CR
P
0.
97
 (0
.96
–0
.99
)
0.
98
 (0
.96
–0
.99
)
 
A
lb
u
m
in
2.
29
 (1
.52
–3
.45
)
1.
70
 (1
.14
–2
.55
)
 
D
ise
as
e 
se
v
er
ity
 (s
ev
er
e 
v
s 
n
o
n
se
v
er
e)
0.
46
 (0
.32
–0
.66
)
0.
59
 (0
.45
–0
.77
)
 
D
ise
as
e 
du
ra
tio
n 
≤2
 y
1.
89
 (1
.12
–3
.18
)
1.
90
 (1
.06
–3
.39
)
 
TN
F 
an
ta
go
ni
st 
ex
po
su
re
0.
63
 (0
.36
–1
.12
)
0.
95
 (0
.52
–1
.72
)
N
OT
E.
 V
ar
ia
bl
es
 e
nt
er
ed
 in
 th
e 
m
ul
tiv
ar
ia
bl
e 
m
od
el
s b
ef
or
e 
ba
ck
w
ar
d 
se
le
ct
io
n 
w
as
 p
er
fo
rm
ed
 in
cl
ud
ed
 th
os
e 
w
ith
 P
 
<
 .2
. T
N
F 
an
ta
go
ni
st 
ex
po
su
re
 w
as
 in
cl
ud
ed
 in
 a
ll 
m
od
el
s i
rre
sp
ec
tiv
e 
o
f P
 
v
al
ue
 a
t 
ea
ch
 st
ep
. F
o
r 
cl
in
ic
al
 re
m
iss
io
n,
 v
ar
ia
bl
es
 in
cl
ud
ed
 g
en
de
r, 
ho
sp
ita
liz
ed
 w
ith
in
 p
re
v
io
us
 1
 y
ea
r, 
CR
P,
 
al
bu
m
in
, s
tru
ct
ur
in
g/
 p
en
et
ra
tin
g 
ph
en
ot
yp
e,
 fi
stu
liz
in
g 
di
se
as
e,
 d
ise
as
e 
se
v
er
ity
,
 
an
d 
co
nc
om
ita
nt
 
st
er
oi
ds
. F
o
r 
co
rt
ic
os
te
ro
id
-fr
ee
 re
m
iss
io
n,
 v
ar
ia
bl
es
 in
cl
ud
ed
 g
en
de
r, 
CR
P,
 
al
bu
m
in
, f
ist
ul
iz
in
g 
di
se
as
e,
 a
nd
 d
ise
as
e 
se
v
er
ity
.
 
Fo
r 
en
do
sc
op
ic
 re
m
iss
io
n,
 v
ar
ia
bl
es
 in
cl
ud
ed
 h
os
pi
ta
liz
ed
 w
ith
in
 p
re
v
io
us
 1
 
ye
ar
,
 
CR
P,
 
al
bu
m
in
, s
tru
ct
ur
in
g/
pe
ne
tra
tin
g 
ph
en
ot
yp
e,
 fi
stu
liz
in
g 
di
se
as
e,
 d
ise
as
e 
se
v
er
ity
,
 
co
n
co
m
ita
nt
 st
er
oi
ds
, a
nd
 c
om
bi
na
tio
n 
th
er
ap
y 
w
ith
 im
m
un
om
od
ul
at
or
.
CI
, c
on
fid
en
ce
 in
te
rv
al
; C
RP
,
 
C-
re
ac
tiv
e 
pr
ot
ei
n;
 H
R,
 h
az
ar
d 
ra
tio
; T
N
F,
 
tu
m
or
 n
ec
ro
sis
 fa
ct
or
.
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2020 February 18.
